Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up

Here, we describe the case of a patient diagnosed with locally advanced breast cancer 8 years ago. Her treatment course was neoadjuvant chemotherapy, followed by mastectomy and then adjuvant radiotherapy and trastuzumab (TTZ). During the use of adjuvant targeted therapy, an incidental pregnancy was...

Full description

Saved in:

Bibliographic Details
Published in:	Anti-cancer drugs Vol. 27; no. 4; pp. 369 - 372
Main Authors:	Andrade, Jurandyr M de, Brito, Luiz G.O, Moises, Elaine C.D, Amorim, Andréa C, Rapatoni, Liane, Carrara, Hélio H.A, Tiezzi, Daniel G
Format:	Journal Article
Language:	English
Published:	England Copyright Wolters Kluwer Health, Inc. All rights reserved 01-04-2016
Subjects:	Adult Antineoplastic Agents - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy, Adjuvant Child Disease-Free Survival Female Follow-Up Studies Humans Male Pregnancy Pregnancy Complications, Neoplastic - drug therapy Pregnancy Complications, Neoplastic - pathology Trastuzumab - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Here, we describe the case of a patient diagnosed with locally advanced breast cancer 8 years ago. Her treatment course was neoadjuvant chemotherapy, followed by mastectomy and then adjuvant radiotherapy and trastuzumab (TTZ). During the use of adjuvant targeted therapy, an incidental pregnancy was diagnosed. Four years later, she developed bone and cerebral metastases, and since then, she has received courses of TTZ, capecitabine, lapatinib, and radiotherapy with intermittent control of the disease. Her 7-year-old son presents a normal physical and long-term neurological developmental curve according to specialized evaluation. This case is unique for several reasonsthe patient received the highest dose of TTZ yet described during pregnancy (4400 mg); there has been a long period of disease-free survival after treatment for locally advanced breast cancer and long overall survival despite successive disease progressions during the metastatic phase of the disease (97 months), and there was a monitored pediatric follow-up period (7 years).
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0959-4973 1473-5741
DOI:	10.1097/CAD.0000000000000344